Summary

The 2012 American Diabetes Association/European Association for the Study of Diabetes position statement for the management of hyperglycemia recommends, as 1 of the 3-drug combinations, the addition of glucagon-like peptide–1 receptor agonists to basal insulin analogs (or conversely, insulin to GLP-1 receptor agonists) after initial therapy with metformin. This article presents the results of the Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes trial [LIRA-ADD2BASAL; NCT01617434], comparing the efficacy and safety of liraglutide versus placebo when added to basal insulin analogs.